Drugs

pp 1–12 | Cite as

Belimumab: A Review in Systemic Lupus Erythematosus

Adis Drug Evaluation
  • 200 Downloads

Abstract

Belimumab (Benlysta®) is a human immunoglobulin G1λ monoclonal antibody that inhibits the binding of soluble B lymphocyte stimulator to B cells. It is the only biological agent currently approved for the treatment of non-renal systemic lupus erythematosus (SLE). Belimumab is approved in the EU, the USA and other countries as add-on therapy in adult patients with active, autoantibody-positive SLE despite standard therapy. In phase III trials, treatment with IV or SC belimumab plus standard therapy was effective in terms of reducing overall disease activity and reducing the incidence and severity of flares, without worsening of patients’ overall condition or the development of significant disease activity in new organ systems. Sustained disease control was maintained during longer-term (up to 10 years) treatment with IV belimumab. Belimumab also demonstrated steroid-sparing effects and was associated with clinically meaningful improvements in health-related quality of life and fatigue. Belimumab was generally well tolerated in clinical trials, with low rates of immunogenicity. In view of the flexibility regarding the route of administration and the convenience of the once-weekly, self-administered, SC regimen, add-on therapy with belimumab is a useful treatment option for patients with active, autoantibody-positive SLE despite standard therapy.

Notes

Acknowledgements

During the peer review process, the manufacturer of belimumab was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Hannah Blair and Sean Duggan are salaried employees of Adis/Springer, are responsible for the article content and declare no relevant conflicts of interest.

Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/DCD8F0603CADACA0.

References

  1. 1.
    Hui-Yuen JS, Li XQ, Askanase AD. Belimumab in systemic lupus erythematosus: a perspective review. Ther Adv Musculoskelet Dis. 2015;7(4):115–21.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Garcia A, De Sanctis JB. A review of clinical trials of belimumab in the management of systemic lupus erythematosus. Curr Pharm Des. 2016;22(41):6306–12.CrossRefPubMedGoogle Scholar
  3. 3.
    Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008;10(5):R109.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Sifuentes Giraldo WA, Garcia Villanueva MJ, Boteanu AL, et al. New targets in systemic lupus (part 2/2). Reumatol Clin. 2012;8(5):263–9.CrossRefPubMedGoogle Scholar
  5. 5.
    European Medicines Agency. Benlysta® (belimumab): summary of product characteristics. 2017. http://www.ema.europa.eu. Accessed 18 Jan 2018.
  6. 6.
    GlaxoSmithKline. Benlysta® (belimumab): US prescribing information. 2017. https://www.accessdata.fda.gov. Accessed 18 Jan 2018.
  7. 7.
    Burness CB, McCormack PL. Belimumab: in systemic lupus erythematosus. Drugs. 2011;71(18):2435–44.CrossRefPubMedGoogle Scholar
  8. 8.
    Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48(11):3253–65.CrossRefPubMedGoogle Scholar
  9. 9.
    Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61(9):1168–78.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–30.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–31.CrossRefPubMedGoogle Scholar
  12. 12.
    Struemper H, Thapar M, Roth D. Population pharmacokinetic and pharmacodynamic analysis of belimumab administered subcutaneously in healthy volunteers and patients with systemic lupus erythematosus. Clin Pharmacokinet. 2017.  https://doi.org/10.1007/s40262-017-0586-5.PubMedGoogle Scholar
  13. 13.
    Struemper H, Chen C, Cai W. Population pharmacokinetics of belimumab following intravenous administration in patients with systemic lupus erythematosus. J Clin Pharmacol. 2013;53(7):711–20.CrossRefPubMedGoogle Scholar
  14. 14.
    Yapa SW, Roth D, Gordon D, et al. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus phase 3 program. Lupus. 2016;25(13):1448–55.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Chatham WW, Wallace DJ, Stohl W, et al. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial. J Rheumatol. 2012;39(8):1632–40.CrossRefPubMedGoogle Scholar
  16. 16.
    Chatham W, Chadha A, Fettiplace J, et al. A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus. Lupus. 2017;26(14):1483–90.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Zhang F, Bae SC, Bass D, et al. A pivotal phase III, randomized, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan, and South Korea [abstract no. 742 plus poster]. Arthritis Rheumatol. 2016;68(Suppl 10):988–9.Google Scholar
  18. 18.
    Tanaka Y, Bass D, Chu M, et al. Effects of belimumab on corticosteroid use in a pivotal phase III, randomised, placebo controlled study in subjects with systemic lupus erythematosus in North East Asia [abstract no. 106 plus poster]. Lupus Sci Med. 2017;4(1):A45–6.Google Scholar
  19. 19.
    Wallace DJ, Ginzler EM, Merrill JT, et al. Sustained safety and efficacy over 10 years with belimumab (BEL) plus standard systemic lupus erythematosus (SLE) therapy (SOC) in patients with SLE [abstract no. OP0232 plus oral presentation]. Ann Rheum Dis. 2017;76(Suppl. 2):150–1.Google Scholar
  20. 20.
    Furie RA, Wallace DJ, Aranow C, et al. 7-year safety and efficacy of belimumab in patients with systemic lupus erythematosus [abstract no. 768]. Arthritis Rheumatol. 2016;68(Suppl 10):1027–8.Google Scholar
  21. 21.
    Strand V, Berry P, Ramachandran S, et al. Long-term impact of belimumab on health-related quality of life and fatigue in patients with systemic lupus erythematosus: up to 7 years of treatment exposure [abstract no. 3235]. Arthritis Rheumatol. 2016;68(Suppl 10):2216–7.Google Scholar
  22. 22.
    van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71(8):1343–9.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Manzi S, Sanchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833–8.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    van Vollenhoven RF, Petri M, Wallace DJ, et al. Cumulative corticosteroid dose over fifty-two weeks in patients with systemic lupus erythematosus: pooled analyses from the phase III belimumab trials. Arthritis Rheumatol. 2016;68(9):2184–92.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Strand V, Levy RA, Cervera R, et al. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis. 2014;73(5):838–44.CrossRefPubMedGoogle Scholar
  26. 26.
    Bruce IN, Urowitz M, van Vollenhoven R, et al. Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. Lupus. 2016;25(7):699–709.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Urowitz M, Ohsfeldt RL, Wielage R, et al. A propensity score-matched study of organ damage in patients with systemic lupus erythematosus from the BLISS long-term extension trials versus the toronto lupus cohort: a post hoc longitudinal analysis [abstract no. 2923]. Arthritis Rheumatol. 2017;69(Suppl. 10):4217–8.Google Scholar
  28. 28.
    Collins CE, Dall’Era M, Kan H, et al. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA. Lupus Sci Med. 2016;3(1):e000118.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Hui-Yuen JS, Reddy A, Taylor J, et al. Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. J Rheumatol. 2015;42(12):2288–95.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Stott-Miller M, Egger P, Eudy A, et al. Impact of belimumab use on flares among patients diagnosed with systemic lupus erythematosus (SLE) in a US commercially insured database: 2010-2014 [abstract no. OP0039]. Ann Rheum Dis. 2016;75(Suppl 2):68.CrossRefGoogle Scholar
  31. 31.
    Schwarting A, Schroeder JO, Alexander T, et al. First real-world insights into belimumab use and outcomes in routine clinical care of systemic lupus erythematosus in Germany: results from the OBSErve Germany study. Rheumatol Ther. 2016;3(2):271–90.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Cortes J, Andreu JL, Calvo J, et al. Evaluation of use of belimumab in clinical practice settings (OBSERVE study) in Spain: health resource utilization and labour absenteeism [abstract no. PSY73]. Value Health. 2014;17(7):A534.CrossRefPubMedGoogle Scholar
  33. 33.
    Touma Z, Sayani A, Pineau CA, et al. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study. Rheumatol Int. 2017;37(6):865–73.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Garcia M, Pons-Estel BA, Babini A, et al. Evaluation of use of belimumab in clinical practice settings (OBSERVE) in Argentina [abstract no. P4.14]. Clin Exp Rheumatol. 2015;33(3 Suppl 90):S31.Google Scholar
  35. 35.
    Parodis I, Sjöwall A, Jönsen A, et al. Decreased disease activity and corticosteroid usage and improved quality of life during belimumab treatment in patients with systemic lupus erythematosus—a prospective real-life observational study [abstract no. 732]. Arthritis Rheumatol. 2015;67(Suppl 10):994.Google Scholar
  36. 36.
    Iaccarino L, Bettio S, Reggia R, et al. Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus. Arthritis Care Res. 2016;69(1):115–23.CrossRefGoogle Scholar
  37. 37.
    Iaccarino L, Andreoli L, Bocci EB, et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J Autoimmun. 2018;86:1–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Fanouriakis A, Adamichou C, Koutsoviti S, et al. Real-life experience with belimumab in systemic lupus erythematosus (SLE): control of disease activity and flares in a multicenter cohort [abstract no. AB0442]. Ann Rheum Dis. 2017;76(Suppl. 2):1204–5.Google Scholar
  39. 39.
    Scheinberg M, de Melo FF, Bueno AN, et al. Belimumab for the treatment of corticosteroid-dependent systemic lupus erythematosus: from clinical trials to real-life experience after 1 year of use in 48 Brazilian patients. Clin Rheumatol. 2016;35(7):1719–23.CrossRefPubMedGoogle Scholar
  40. 40.
    Parodis I, Sjowall C, Jonsen A, et al. Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. Autoimmun Rev. 2017;16(4):343–51.CrossRefPubMedGoogle Scholar
  41. 41.
    Pascoe K, Lobosco S, Bell D, et al. Satisfaction and impact associated with the addition of belimumab to systemic lupus erythematosus (SLE) treatment: a cross-sectional survey of US rheumatologists and their patients [abstract no. 741]. Arthritis Rheumatol. 2015;67(Suppl 10):1005–7.Google Scholar
  42. 42.
    Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2017;69(5):1016–27.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Doria A, Stohl W, Schwarting A, et al. Safety of subcutaneous belimumab in patients with systemic lupus erythematosus: a 6-month open-label extension study [abstract no. SAT0231]. Ann Rheum Dis. 2017;76(Suppl. 2):861.Google Scholar
  44. 44.
    Doria A, Pobiner B, Eastman W, et al. Subcutaneous belimumab plus standard of care demonstrated improvement in multiple organ domains versus placebo plus standard of care in patients with active systemic lupus erythematosus (SLE) [abstract no. 2590]. Arthritis Rheumatol. 2017;69(Suppl. 10):3731–3.Google Scholar
  45. 45.
    Van Vollenhoven RF, Thompson A, Pobiner B, et al. The effect of subcutaneous belimumab on corticosteroid use in patients with systemic lupus erythematosus (SLE): a phase 3, randomized, placebo-controlled study [abstract no. 2604]. Arthritis Rheumatol. 2017;69(Suppl. 10):3757–8.Google Scholar
  46. 46.
    Krishna M, Nadler SG. Immunogenicity to biotherapeutics—the role of anti-drug immune complexes. Front Immunol. 2016;7:21.  https://doi.org/10.3389/fimmu.2016.00021.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Arthritis Rheum. 1999;42(9):1785–96.Google Scholar
  48. 48.
    Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics. Ann Rheum Dis. 2008;67(2):195–205.CrossRefPubMedGoogle Scholar
  49. 49.
    Kleinmann JF, Tubach F, Le Guern V, et al. International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmun Rev. 2017;16(6):650–7.CrossRefPubMedGoogle Scholar
  50. 50.
    National Institute for Health and Care Excellence. Belimumab for treating active autoantibody-positive systemic lupus erythematosus. 2016. https://www.nice.org.uk. Accessed 18 Jan 2018.
  51. 51.
    American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials. Measures of overall disease activity. Arthritis Rheum. 2004;50(11):3418–26.CrossRefGoogle Scholar
  52. 52.
    Dashiell-Aje E, Harding G, Pascoe K, et al. Patient evaluation of satisfaction and outcomes with an autoinjector for self-administration of subcutaneous belimumab in patients with systemic lupus erythematosus. Patient. 2018;11(1):119–29.CrossRefPubMedGoogle Scholar
  53. 53.
    Lee YH, Song GG. Comparative efficacy and safety of intravenous or subcutaneous belimumab in combination with standard therapy in patients with active systemic lupus erythematosus: a Bayesian network meta-analysis of randomized controlled trials. Lupus. 2017;27(1):112–9.CrossRefPubMedGoogle Scholar
  54. 54.
    Jordan N, D’Cruz DP. Belimumab for the treatment of systemic lupus erythematosus. Expert Rev Clin Immunol. 2015;11(2):195–204.CrossRefPubMedGoogle Scholar
  55. 55.
    Vallejo-Aparicio LA, Diaz-Cerezo S, Parrondo J, et al. Cost-effectiveness analysis of belimumab in the treatment of adult systemic lupus erythematosus (SLE) patients with positive biomarkers in Spain [abstract no. PSY53]. Value Health. 2014;17(7):A530.CrossRefPubMedGoogle Scholar
  56. 56.
    Athanasakis K, Karampli E, Ollandezos M, et al. Belimumab for the treatment of systemic lupus erythematosus (SLE) in Greece: a cost-effectiveness and cost-utility analysis [abstract no. PSY64]. Value Health. 2014;17(7):A532–3.CrossRefPubMedGoogle Scholar
  57. 57.
    Pierotti F, Palla I, Treur M, et al. Assessment of the economic impact of belimumab for the treatment of systemic lupus erythematosus in the Italian setting: a cost-effectiveness analysis. PLoS One. 2015;10(10):e0140843.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016;12(10):605–20.CrossRefPubMedGoogle Scholar
  59. 59.
    US National Institutes of Health. 2017. http://www.clinicaltrials.gov. Accessed 18 Jan 2018.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations